Printer Friendly

MERRIMACK COMPLETES ENROLLMENT FOR MM-093 PHASE IIA.

Merrimack Pharmaceuticals, Inc., Cambridge, Mass., has completed enrollment for a Phase IIa pilot study in patients with rheumatoid arthritis with its immunomodulatory drug candidate, MM-093, a recombinant version of human alpha-fetoprotein (AFP). The results of the study are expected to be available during the first quarter of 2005.

The randomized, double-blind, placebo-controlled, Phase IIa study is on- going at Kings College Hospital in London. The goal of the study is to examine the safety and tolerability of MM-093 in rheumatoid arthritis patients. Each patient receives a once weekly injection for 12 weeks and then is followed for an additional 4 weeks. In addition to determining the safety of MM-093, patients are evaluated for changes in their disease state using the ACR scale, the clinical standard for drug development in rheumatoid arthritis.

"This pilot study is our first clinical investigation of MM-093 specifically for the treatment of rheumatoid arthritis," said Dr. Brian Hamilton, vice president of Clinical and Regulatory Affairs. The study will aid Merrimack in designing future clinical studies in rheumatoid arthritis, as well as studies in other autoimmune disease patient populations. The development of MM-093 will be focused on diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis -- areas in which published and proprietary pre-clinical data provide a compelling rationale for its use, and in which significant unmet medical needs still exist."

Merrimack has the exclusive worldwide license to a strong intellectual property estate around MM-093. The portfolio surrounding MM-093 includes six issued patents and several pending applications, both in the U.S. and internationally, which cover composition of matter, production methods and therapeutic and non-therapeutic uses of the drug.

Merrimack currently is manufacturing MM-093 under a strategic alliance with GTC Biotherapeutics. MM-093 was purified from the milk of transgenic goats, which carry the MM-093 gene. "The GTC system provides Merrimack with an economical system that produces active product in a form from which MM-093 can be readily purified," commented Mark Moody, Merrimack's Director of Operations.

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. It's lead compound, MM-093 is currently in a pilot clinical study for patients with rheumatoid arthritis. Developed with the help of leading scientists from MIT and Harvard, the company's proprietary Network Biology(TM) discovery platform enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately held company based in Cambridge, Massachusetts.

For more information, visit http://www.merrimackpharma.com or call 617/441-1000.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:1USA
Date:Oct 1, 2004
Words:437
Previous Article:AVIAN INFLUENZA VACCINE TRIALS INITIATED IN AUSTRALIA.
Next Article:ABLYNX AND GENENCOR FORM ONCOLOGY COLLABORATION.
Topics:


Related Articles
Arris' Asthma Drug APC-366 Shows Promising Results.
AVEXA IN-LICENSES PHASE II HIV DRUG FROM SHIRE.
Merrimack Pharmaceuticals Secures $9 Million Credit Facility from Hercules Technology Growth Capital, Inc.
GTC Biotherapeutics Enters Agreement for Further Clinical Production of MM-093 for Merrimack Pharmaceuticals.
GTC Biotherapeutics Reports Third Quarter 2005 Financial Results.
Dyax Announces Positive Final Results from Phase I Trial of Subcutaneous DX-88; Positive Experience with Subcutaneously Administered DX-88 in the...
MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL.
Merrimack Pharmaceuticals to Present on Infotrieve's E-Lab Notebook at Upcoming Lab Informatics Conference.
Rapid manufacturing produces custom lingual orthodontic appliances.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters